North America Infectious Disease Therapeutics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)

No. of Pages: 100    |    Report Code: BMIRE00030503    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Infectious Disease Therapeutics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Infectious Disease Therapeutics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Infectious Disease Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Rising Prevalence of Infectious Disease
  • 5.1.2 Increasing Focus on Funding and R&D for Infectious Disease Therapeutics
5.2 Market Opportunities
  • 5.2.1 Growing Opportunities in Developing Nations
5.3 Future Trends
  • 5.3.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine is the Recent Trend Witnessed in the Market
5.4 Impact of Drivers and Restraints

6. North America Infectious Disease Therapeutics Market Regional Analysis

6.1 North America Infectious Disease Therapeutics Market Overview
6.2 North America Infectious Disease Therapeutics Market Revenue 2020-2030 (US$ Million)
6.3 North America Infectious Disease Therapeutics Market Forecast Analysis

7. North America Infectious Disease Therapeutics Market Analysis – by Drug Class

7.1 Anti-viral
  • 7.1.1 Overview
  • 7.1.2 Anti-viral: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Anti-Bacterial
  • 7.2.1 Overview
  • 7.2.2 Anti-Bacterial: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Anti-Fungal
  • 7.3.1 Overview
  • 7.3.2 Anti-Fungal: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Infectious Disease Therapeutics Market Analysis – by Indication

8.1 HIV
  • 8.1.1 Overview
  • 8.1.2 HIV: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.2 Hepatitis
  • 8.2.1 Overview
  • 8.2.2 Hepatitis: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Tuberculosis
  • 8.3.1 Overview
  • 8.3.2 Tuberculosis: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Influenza
  • 8.4.1 Overview
  • 8.4.2 Influenza: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.5 HPV
  • 8.5.1 Overview
  • 8.5.2 HPV: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)

9. North America Infectious Disease Therapeutics Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies
  • 9.1.1 Overview
  • 9.1.2 HPV: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.2 Retail Pharmacies
  • 9.2.1 Overview
  • 9.2.2 HPV: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)

10. North America Infectious Disease Therapeutics Market – North America Analysis

10.1 North America
  • 10.1.1 North America Infectious Disease Therapeutics Market Breakdown, by Key Country, 2023 and 2030 (%)
  • 10.1.1.1 North America Infectious Disease Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.1.1 US: North America Infectious Disease Therapeutics Market Breakdown, by Drug Class
    • 10.1.1.1.2 US: North America Infectious Disease Therapeutics Market Breakdown, by Indication
    • 10.1.1.1.3 US: North America Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.2 Canada: North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.2.1 Canada: North America Infectious Disease Therapeutics Market Breakdown, by Drug Class
    • 10.1.1.2.2 Canada: North America Infectious Disease Therapeutics Market Breakdown, by Indication
    • 10.1.1.2.3 Canada: North America Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.3 Mexico : North America Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Infectious Disease Therapeutics Market Breakdown, by Drug Class
    • 10.1.1.3.2 Mexico : North America Infectious Disease Therapeutics Market Breakdown, by Indication
    • 10.1.1.3.3 Mexico : North America Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Infectious Disease Therapeutics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 AbbVie Inc
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Astellas Pharma Inc
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Bayer AG
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 BioCryst Pharmaceuticals Inc
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 F. Hoffmann-La Roche Ltd
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Gilead Sciences Inc
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 GSK Plc
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Merck & Co Inc
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Pfizer Inc
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Shionogi & Co Ltd
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - N Market

1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. BioCryst Pharmaceuticals Inc
5. F. Hoffmann-La Roche Ltd
6. Gilead Sciences Inc
7. GSK Plc 
8. Merck & Co Inc
9. Pfizer Inc
10. Shionogi & Co Ltd

north-america-infectious-disease-therapeutics-market